/kg CD34
؉ cells. In cells in apheresis products, but whether this cost-and timeconsuming technique improves survival is currently under three patients unselected back-up PBSC had to be transfused along with selected CD34
؉ cells because of a investigation.
14-16
We report here on our experience in 28 patients suffering CD34
؉ cell number Ͻ0.5 ؋ 10 6 /kg. G-CSF (10 g/kg) was started on day ؉1 and all patients engrafted within from poor-risk malignancies, for whom CD34 , n = 19) or other dose-intensive progression/relapse as compared to the historical controls. We observed five episodes of serious opportunistic chemotherapy regimens (n = 6) and rhG-CSF (10 g/kg). By December 1996, 22 patients had been autografted with infections (three pulmonary fungal infections, two cases of cryptosporidiosis) after the take. Four of these purified CD34 + cells. The characteristics of these 22 patients are listed in The historical control group consisted of 18 consecutive administered. All patients underwent a non-absorbable oral gut decontamination with vancomycin, gentamycin and patients with poor-risk malignancies according to the above-mentioned criteria autografted at our institution nystatin. Pneumocystis carinii prophylaxis was performed with trimethoprim-sulfamethoxazole given in a 10-day between 1983 and 1996 (solid tumor, n = 11; lymphoma, n = 3; multiple myeloma, n = 4). The two groups were not course before transplantation and after the take. Cytomegalovirus (CMV) pneumonia prophylaxis consisted of different with respect to diagnosis, median age at transplant, median time to transplantation, lines of previous infusions of CMV hyperimmunoglobulin (1 ml/kg) every other week until day +100. Irradiated (25 Gy), leukocytetreatment, and median post-transplant follow-up (P = NS). There were significantly more females in the historical condepleted red cell and platelet transfusions from single donors were administered when hemoglobin levels were 7.0 trol group (11/18 vs 8/22, P = 0.0027) and significantly more patients in the control group received a TBI-containg/dl or less and platelets were 20 ϫ 10 9 /l or less. Pretransplant conditioning regimens consisted of CY ing conditioning regimen (10/18 vs 4/22 in the CD34 2 ) in two breast cancer patients. Forty-eight hours after completing pretransplant conditioning, purified CD34 + cells were rapidly thawed and given CD34 quantitation intravenously. All patients received G-CSF (10 g/kg) starting on day +1 given as a 2-h infusion until leukocyte Cell counts were performed using a fluorescence-activated cell sorter (FACS Vantage; Becton Dickinson, Palo Alto, engraftment, defined as the first of 2 consecutive days with leukocyte counts Ͼ1.0 ϫ 10 9 /l (take). In three patients CA, USA). CD34 + cells were determined daily after stem cell mobilization with high-dose chemotherapy in hepadditional unselected back-up PBMC were transfused because of the low number of CD34 + cells arinized venous blood samples when leukocytes reached values Ͼ1.0 ϫ 10 9 /l, and in the leukapheresis products, the (Ͻ0.5 ϫ 10 6 /kg). Patients with multiple myeloma received recombinant flow-through fraction from the CEPRATE column, and in the adsorbed fraction using a phycoerythrin (PE)-conjuinterferon-␣-2b (Intron A; Schering International, Vienna, Austria) subcutaneously at a dosage of 2 mega units three gated anti-human CD34 MoAb (HPCA-2; Becton Dickinson, Palo Alto, CA, USA). Peripheral blood mononuclear times weekly starting after stable engraftment, defined as leukocyte counts Ͼ3 ϫ 10 9 /l and platelets Ͼ45 ϫ 10 9 /l. cells (PBMC) from heparinized venous blood samples were obtained by Ficoll-Isopaque (Lymphoprep; Nycomed, Interferon treatment was maintained until disease progression. Patients with radiosensitive bulky or metastatic Oslo, Norway) gradient centrifugation (400 g for 30 s at room temperature). After two washes cells were resusdisease at the time of autografting received involved field irradiation within the first 3 months. pended in phosphate-buffered saline (PBS) containing 1% bovine serum albumin and sodium azide and simultaneously stained with anti-CD34 MoAb and fluorescein
Response criteria (FITC)-conjugated anti-CD45 MoAb (HLe-1; Becton Dickinson) for 20 min at 4°C. Isotype-matched control antiIn patients with multiple myeloma, complete remission (CR) was defined as less than 5% bone marrow plasma bodies were processed in parallel. After two washes, the percentage of CD34 + cells was determined by gating on cells, no measurable paraprotein in serum and/or urine by immunoelectrophoresis or immunofixation, and no eviforward (FSC) and side scatter (SSC) characteristics and CD45 staining. A minimum of 30 000 events were collected dence of progressive bony lesions. Partial response (PR) was defined as у75% reduction of bone marrow plasmain list mode and processed with a CELLQuest software. MNC from the leukapheresis products, the flow-through cytosis and/or paraprotein levels without progressive bony lesions. Stable disease (SD) was defined as р75% fraction from the CEPRATE column and from the adsorbed 4 For patients with lymphoma or solid tumors CR independence after a median of 56 (range 10-180) days. As shown in Table 3 , in patients receiving Ͻ2.0 ϫ 10 6 /kg was defined as the disappearance of all clinical and radiographic evidence of disease. PR was defined as reduction CD34 + cells leukocyte engraftment was significantly delayed (median day number until take 15, range 11-22) of measurable disease by more than 50% without the appearance of new lesions, SD was defined as less than as compared to patients receiving Ͼ2.0 ϫ 10 6 /kg CD34 + cells (median day number until take 11, range 10-13, 50% tumor reduction and PD as the appearance of any new tumor lesion and/or increase of measurable disease by more P = 0.0126). Time to platelet transfusion independence was also significantly delayed in patients autografted with than 25%.
Ͻ2.0 ϫ 10 6/ kg CD34 + cells (median days 118, range 16-180) as compared to patients receiving Ͼ2.0 ϫ 10 6 /kg Statistics CD34 + cells (median days 27, range 10-170, P = 0.0077, Table 3 ). Both time to leukocyte engraftment and platelet For the comparison of the distribution between the study and control group we used the 2 test for categorical varitransfusion independence were significantly inversely correlated to the CD34 + cell number transfused (P = 0.008, ables and the Wilcoxon test for continuous variables. Unadjusted Kaplan-Meier estimates were used to display the r = −0.6, and P = 0.0011, r = -0.7, respectively, Figure 1a and b). incidences of overall survival, progression-free survival and transplant-related mortality. 17 Progression-free and overall The engraftment data of the CD34 + group of patients were compared with that of a historical group of patients survival were defined as the time from the day of stem cell transplantation (day 0) until disease progression or death.
(n = 18) who received unmanipulated ABMT Ϯ PBSCT.
Time to leukocyte or platelet recovery were not different Correlations between CD34
+ cell number and time until take or platelet transfusion independence were computed for both groups with the exception of a significantly more rapid leukocyte engraftment in patients autografted with using the Spearman rank correlation coefficient.
18 For comparisons of time to engraftment between the independent Ͼ2.0 ϫ 10 6 /kg purified CD34 + cells (median days until leukocytes Ͼ1.0 ϫ 10 9 /l for the CD34 + group 11, range 10-groups we used the Wilcoxon rank-sum test. 19 + cell number (Ͻ0.5 ϫ 10 6 /kg). All three patients had multiple All other patients autografted in complete remission remained progression-free throughout the observation perlines of treatment prior to transplantation with either alkylating agent-containing regimens for more than a year iod ( Table 1 ). The median follow-up for the CD34 + -selected group was 10 months (range 3-28) and 8 months (range (UPN 161 and 164) or had a relapse after ABMT with a Table 2 Apheresis products processing data in 28 patients with poor-risk hematological malignancies and solid tumors 1-127) for the unselected historical control group (difference statistically not significant). Overall survival for the CD34 + -selected group was 57 and 16% for the historical controls (Figure 2a) . The relapse/progression rate after CD34 + -selected PBSCT was 25% as compared to 75% of the historical controls treated with unselected ABMT Ϯ PBSCT (Figure 2c) .
Only one patient of the CD34 + -selected cohort died from treatment-related complications (Figure 2b ). This patient (UPN 171) experienced intestinal cryptosporidiosis 52 days after reinfusion of 1.26 ϫ 10 6 /kg CD34 + cells. Treatment with paromomycin was unsuccessful. He developed pulmonary cryptosporidiosis and died of respiratory failure on day +118 while being in complete remission from lymphoma. Four other patients developed serious opportunistic infections after the take (three pulmonary fungal infections, UPN 190, day +60; UPN 201, day +21; UPN 203, day +32, and one Cryptosporidium infection, UPN 177, day +71) but none of these patients died due to infection. Three of these four patients had also been reinfused with Ͻ2.0 ϫ 10 6 /kg CD34 + cells. 
Discussion
Autologous transplantation with mobilized PBSC has been shown to be superior to BM stem cells with respect to engraftment kinetics but without any significant differences in relapse incidence, transplant-related mortality or survival. 1, 3, 8, 20 Interestingly, in one recent study an even higher relapse incidence after unpurged PBSCT for lymphoma was reported as compared to antibody-purged ABMT. 1 Concomitant tumor cell mobilization by the stem cell mobilization procedure has been noticed and tumor cells contaminating autografts have been identified by gene-marking studies as a cause of relapse after ABMT/PBSCT. [9] [10] [11] [12] [13] Positive selection of CD34 + cells is one possibility to reduce the quantity of contaminating tumor cells. However, the questions to be addressed with this technique include the following: is it possible to mobilize a sufficient number of CD34 + cells even in extensively pretreated, poor-risk patients, do CD34 + -selected stem cells mediate a faster hematopoietic regeneration than unseparated stem cells, and is there any advantage with respect to overall survival, transplant-related mortality or relapse incidence after obtained had received у3 lines of previous treatment including either alkylating agents or irradiation or had bone marrow involvement of their underlying disease, factors that have all been identified as significant determinants of progenitor cell yield. 2, 20, 21 Additionally, three of these nine patients also experienced prolonged treatment with IFN-␣ prior to stem cell collection. Suppression of myeloid progenitors by interferon treatment has been demonstrated and must be taken into account as an additional factor adversely affecting stem cell harvests. 22 The rates of neutrophil and platelet recovery of the entire CD34 + -selected group were equivalent when compared with those of the historical control group. These results confirm the observations made in two other small series using positively selected CD34
+ cells for hematopoietic reconstitution after high-dose chemotherapy.
14,23 Our observation of a significantly delayed platelet recovery in patients autografted with Ͻ2.0 ϫ 10 6 /kg purified CD34 + cell dose and suggests that G-CSF alone is not sufficient to induce a parallel increase of both granulocytes and platelets in this group of patients. 24 Whether the use of post-transplant G-CSF can even delay platelet recovery in patients receiving a low CD34
+ cell dose as it was demonstrated in a large retrospective analysis by the Seattle group remains to be shown in a prospective randomized trial. 2 The third question of whether there is any survival advantage for patients autografted with purified CD34 + cells due to the tumor cell purging effect will not be answered until controlled prospective randomized trials have been completed. However, there was a trend towards a better overall survival due to a lower relapse/progression probability after CD34 25-27 Furthermore, the stem cell mobilization procedure itself using high-dose CY might be a good prognostic parameter and might have contributed to the beneficial effects of CD34 + selection on overall survival and relapse incidence in our poor-risk patients.
Another important aspect of CD34 + selection deals with the concomitant T cell depletion and its possible consequences on immune reconstitution kinetics after CD34 + -selected PBSCT, although purified, allogeneic CD34
+ cells devoid of mature T and B lymphocytes have been shown to restore lymphopoiesis in lethally irradiated non-human primates.
28
Whether lymphocyte reconstitution after CD34 + -selected PBSCT is delayed or even is a function of CD34 + cell number resulting in a higher rate of infectious complications, as it is observed after T cell depletion in the allogeneic setting, is unknown. 29 Preliminary observations at our institution reveal a profound delay of qualitative and quantitative T lymphocyte reconstitution, especially of CD4 + cells, within the first 100 days after CD34 
